Quest Diagnostics Acquires ReproSource, Extending Into Advanced Fertility Diagnostics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
Piper Jaffray Reiterates Neutral on Quest Diagnostics (DGX) Following Announced Quest-Oxford Deal
September 25, 2018 1:17 PM EDTPiper Jaffray analyst, William Quirk, reiterated a Neutral rating and $110.00 price target on Quest Diagnostics (NYSE: DGX) following the company's announcement that it has acquired the US laboratory services business from Oxford Immunotec, paying $170M for about ~$55M in tick-borne disease and TB revenue.... More



